Bixiye
QP83-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Kerendia®
Taariikhda uu dhaqangalayo barnaamijka: Okt 27, 2021
Natiijooyinka Raadinta
Soo bandhiga 2041 - 2050 ee natiijooyinka 3690
Bixiye
QP84-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) Criteria: Cholestasis Pruritis
Taariikhda uu dhaqangalayo barnaamijka: Okt 27, 2021
Bixiye
Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blocker (Corlanor) - Commercial
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo barnaamijka: Okt 01, 2024
Bixiye
Hemophilia Factor IX - Commercial
Prior Authorization, Quantity Limit
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2024
Bixiye
2021 November Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2021
Bixiye
QP85R1-21 Resolution Process for Providers Serving Minnesota Health Care Programs (MHCP) Members
Taariikhda uu dhaqangalayo Barnaamijka: May 11, 2022
Bixiye
Proton Pump Inhibitors (PPI's) - Medicaid
Quantity Limit
Taariikhda uu dhaqangalayo barnaamijka: Okt 01, 2024
Bixiye
Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors - Medicaid - Effective Date 02/01/2025
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: 01, Feb 2025
Bixiye
Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors - Commercial - Effective Date 02/01/2025
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: 01, Feb 2025